Name | Odulimomab |
---|
Description | Odulimomab (anti-LFA1) is an anti-LFA-1 monoclonal antibody. Odulimomab inhibits proliferation of T lymphocyte and shows protective effects against ischemia and reperfusion injury. Odulimomab can be used for the research of transplant rejection and immunological disease[1][2]. |
---|---|
Related Catalog | |
In Vitro | Odulimomab 在体外抑制 T 淋巴细胞增殖,以及 T 和自然杀伤细胞 (NK) 的细胞毒性和抗体产生[2]。 |
In Vivo | Odulimomab (1.5 和 0.75 mg/kg;腹腔注射,第 1 次治疗 1.5 mg/kg,然后每天注射 0.75 mg/kg) 对缺血和再灌注损伤有保护作用,对移植后肾功能有所修复[1]。 Animal Model: Cynomolgus Monkeys with renal damage ischemia and kidney autotransplantation[1] Dosage: 1.5 and 0.75 mg/kg Administration: Intraperitoneal injection; 1.5 mg/kg for the first dose and after pedicle clamping followed by daily injection of 0.75 mg/kg until sacrifice Result: Decreased the creatinine level after ischemia and autotransplantation for 3 days and increased the potassium fraction reabsorption. |
References |
No Any Chemical & Physical Properties |